Olema Pharmaceuticals
Develops oral therapies for breast cancer and other endocrine-driven tumors.
$10.50
After-hours close+0.22 (+2.14%)
At close$10.28(−4.73%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 118.05%Insiders 2.18%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 87.35M · Float 70.84M · 81.1% free float
Institutions13F, as of Jun 30, 2026
200 holders · 103.12M shares · 26 new positions · 100 increased · 60 reduced · 40 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| FMR LLC | 12.14M | 13.90% | +1.76M | Aug 13, 2026 |
| Paradigm Biocapital Advisors LP | 8.67M | 9.93% | +650.0K | Aug 14, 2026 |
| Jupiter Topco LLC | 7.09M | 8.12% | +7.09Mnew | Aug 14, 2026 |
| Bain Capital Life Sciences Investors, LLC | 7.09M | 8.11% | −388.0K | Aug 14, 2026 |
| BlackRock, Inc. | 6.71M | 7.69% | +1.06M | Aug 7, 2026 |
| BVF Inc/IL | 5.30M | 6.06% | 0 | Aug 14, 2026 |
| Siren, L.L.C. | 4.86M | 5.56% | +100.0K | Aug 13, 2026 |
| State Street Corp | 4.32M | 4.94% | +378.2K | Aug 7, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| FMR LLC | 12.50% | 10.00M | 13G | Mar 6, 2026 ↗ |
| Paradigm BioCapital Advisors LP | 9.99% | 7.43M | 13G | Feb 14, 2025 ↗ |
| Janus Henderson Group PLC | 8.20% | 7.11M | 13G | May 15, 2026 ↗ |
| Bain Capital Life Sciences Opportunities IV, L.P. | 8.15% | 7.47M | 13G | May 15, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Cyrus Harmon | director | 819.8K | 0.94% | Jul 27, 2026 |
| David C. Myles | officer: CH. DISCOV. & NON-CLIN DEV OFF | 687.6K | 0.79% | Jan 14, 2026 |
| Sean Bohen | director, officer: President and CEO | 237.7K | 0.27% | Dec 30, 2025 |
| Shane William Charles Kovacs | officer: CH. OPERATING & FINANCIAL OFF. | 139.7K | 0.16% | Jan 15, 2026 |
| Sasha Lu Austin | officer: VP of Finance and Controller | 16.2K | 0.02% | Feb 17, 2026 |
| Naseem Zojwalla | officer: Chief Medical Officer | 4.5K | 0.01% | Dec 23, 2025 |
| Shawnte Mitchell | officer: CHIEF LEGAL OFFICER | 233 | 0.00% | Mar 5, 2026 |
4 ten-percent owners hold 9.20M shares by Form 4, outside the officers-and-directors figure above · 6 people have not refiled in the last 18 months (4.73M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jul 24, 2026 | Cyrus Harmondirector | Sale | 12,500 | $11.71 | 702,770 |
| Jul 23, 2026 | Cyrus Harmondirector | Sale | 12,500 | $11.58 | 715,270 |
| Mar 3, 2026 | Shawnte Mitchellofficer: CHIEF LEGAL OFFICER | Sale | 15,000 | $23.01 | 0 |
| Mar 4, 2026 | Shawnte Mitchellofficer: CHIEF LEGAL OFFICER | Sale · 2 lots | 25,000 | $24.25 | 233 |
| Jan 20, 2026 | Cyrus Harmondirector | Sale | 10,000 | $26.88 | 727,770 |
| Jan 14, 2026 | Cyrus Harmondirector | Sale | 3,489 | $29.12 | 737,770 |
| Jan 15, 2026 | Shane William Charles Kovacsofficer: CH. OPERATING & FINANCIAL OFF. | Sale | 100,000 | $28.73 | 139,727 |
| Jan 13, 2026 | Shane William Charles Kovacsofficer: CH. OPERATING & FINANCIAL OFF. | Sale | 3,822 | $28.01 | 239,727 |
| Jan 12, 2026 | David C. Mylesofficer: CH. DISCOV. & NON-CLIN DEV OFF | Sale | 10,000 | $28.34 | 144,846 |
| Jan 14, 2026 | David C. Mylesofficer: CH. DISCOV. & NON-CLIN DEV OFF | Sale · 2 lots | 50,000 | $28.87 | 542,761 |
CongressHouse and Senate disclosures
Not reported.